Ipsen's Experimental Drug Fails in Mid-Stage Trial

27 days ago

Louise Moon

"They are so just just a quick one on them. Uh they uh their mid-stage trial for one of their experimental drugs uh failed essentially. So this was for an oral drug for a very rare bone disease and it didn't meet the primary end points. The study had gone on for 5 years um and it's now going to be closed. Analysts are saying the hopes are dashed for developing this treatment. It was one of the few tools Ipsen had to offset a lot of competition, highlighting the need for M&A to boost growth. So, as you say, shares are falling quite heavily."

Ipsen's mid-stage trial for an experimental oral drug intended for a rare bone disease has failed to meet its primary endpoints after a 5-year study, dashing development hopes. This outcome puts pressure on the company to pursue M&A strategies to counteract competitive challenges, with shares falling significantly.

Related Stocks